Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study
ABSTRACT Background: There is a need for biomarkers of dementia in PD. Objectives: To determine if the levels of the main CSF proteins and their ratios are associated with deterioration in cognition and progression to dementia in the short to mid term. Methods: The Parkinson's Progression Marke...
Saved in:
| Published in | Movement disorders Vol. 33; no. 11; pp. 1809 - 1813 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.11.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Summary: | ABSTRACT
Background: There is a need for biomarkers of dementia in PD.
Objectives: To determine if the levels of the main CSF proteins and their ratios are associated with deterioration in cognition and progression to dementia in the short to mid term.
Methods: The Parkinson's Progression Markers Initiative database was used as an exploratory cohort, and a center‐based cohort was used as a replication cohort. Amyloid ß1‐42, total tau, threonine‐181 phosphorylated tau, and α‐synuclein in the CSF and the ratios of these proteins were assessed.
Results: In the Parkinson's Progression Markers Initiative cohort (n = 281), the total tau/amyloid ß1‐42, total tau/α‐synuclein, total tau/amyloid ß1‐42+α‐synuclein, and amyloid ß1‐42/total tau ratios were associated with a risk of progression to dementia over a 3‐year follow‐up. In the replication cohort (n = 40), the total tau/α‐synuclein and total tau/amyloid ß1‐42+α‐synuclein ratios were associated with progression to dementia over a 41‐month follow‐up.
Conclusion: Ratios of the main proteins found in PD patient brain inclusions that can be measured in the CSF appear to have value as short‐ to mid‐term predictors of dementia. © 2018 International Parkinson and Movement Disorder Society |
|---|---|
| Bibliography: | This study was funded by Basque Country Government research grants (2011111074 and SAIOTEK 2012 S‐ PE12BN012). Dr. Delgado‐Alvarado held a Predoctoral Research fellowship from the Government of the Basque Country, and he received a research award from the Fundación Jesús de Gangoiti Barrera. Dr. Dacosta‐Aguayo holds a grant (MB‐1606‐08779) from the National Multiple Sclerosis Society, USA. Dr. Navalpotro‐Gómez holds a Río Hortega grant from the ISCIII, Spain. Jimenez‐Urbieta holds a Predoctoral Research fellowship from the Government of the Basque Country. Full financial disclosures and author roles may be found in the online version of this article. Belén Gago: Universidad de Málaga, Instituto de Investigación Biomédica, Facultad de Medicina, Málaga, Spain Relevant conflicts of interest/financial disclosures Funding agencies Manuel Delgado‐Alvarado: Neurology Department, Sierrallana Hospital, Torrelavega, Spain; Psychiatry Research Area, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain Biomedical Research Networking Center for Mental Health (CIBERSAM), Madrid, Spain Rosalía Dacosta‐Aguayo: Department of Physical Medicine and Rehabilitation, Rutgers, New Jersey Medical School, Newark, New Jersey, Neuropsychology and Neuroscience / NNL Lab Kessler Foundation, East Hanover, New Jersey, USA Dr Delgado‐Alvarado received honoraria for travel and accommodation to attend scientific meetings from UCB. Dr Rodriguez‐Oroz received honoraria for lectures, travel and accommodation to attend scientific meetings from Abbvie, TEVA and Boston Scientific, and she received financial support for her research from Spanish national and local government bodies: the Institute of Health Carlos III, the Government of the Basque Country, Diputacion Foral Guipuzcoa and CIBERNED. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 0885-3185 1531-8257 |
| DOI: | 10.1002/mds.27518 |